View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
April 15, 2020updated 16 Apr 2020 3:58pm

US FDA grants EUA to Ortho’s total antibody assay for Covid-19

The US Food and Drug Administration (FDA) has granted emergency use authorisation (EUA) to Ortho Clinical Diagnostics' total antibody assay, the VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total Reagent Pack and Calibrators to detect coronavirus (Covid-19).


Visit our Covid-19 microsite for the latest coronavirus news, analysis and updates

Free Report
img

Build resilience in the face of COVID-19 disruption

COVID-19 has already affected our lives forever. The way we work, shop, eat, seek medical advice, and socialize will all be different in the future. Quite how different remains to be seen, but all industries must plan for multiple eventualities. Are you interested in actionable insights on the business challenges induced by the pandemic? GlobalData's cross-sector report analyzes the significance of this major disruptive theme across industry verticals. It provides side-by-side research of alternative datasets to present you with unique quantitative analysis of the effects of COVID-19 and how these differ across sectors. Additionally, it offers qualitative analysis of each sector and analyzes COVID-19’s impact on leading companies. Whatever your company’s imminent strategic plans, the long-lasting impact of COVID-19 must not be overlooked. Find out how to futureproof your business operations – download our report today.
by GlobalData
Enter your details here to receive your free Report.

F ollow the latest updates of the outbreak on our timeline.


The US F ood and Drug Administration (F DA) has granted emergency use authorisation (EUA) to Ortho Clinical Diagnostics’ total antibody assay, the VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total Reagent Pack and Calibrators to detect coronavirus (Covid-19).

This total antibody test helps to identify the currently infected or previously exposed individuals who may have developed an immunity.

When combined with information from a molecular test, it monitors disease progression by measuring when antibodies appear in the blood.

It can also help screen plasma donations for convalescent plasma therapy, which assists critically ill patients in fighting the virus.

F urthermore, the test will enable medical professionals and epidemiologists to better understand the spread of the disease. It is considered to be an important tool for aiding vaccine development efforts to monitor immune responsiveness.

Ortho Clinical Diagnostics CEO Chris Smith said: “Ortho is proud to be working toward large-scale solutions that will help people return to work, reducing the strain on both employees and the economy as a whole.

“Our focus on improving patients’ lives through diagnostics led us to rapidly develop this test, providing one of the key resources needed for diagnosing and treating Covid-19.”

The test can be run on Ortho’s laboratory analyser, the VITROS XT 7600 Integrated System, the VITROS 3600 Immunodiagnostic System and the VITROS 5600 Integrated System. It will soon be available on VITROS ECi/ECiQ Immunodiagnostic Systems.

These VITROS Systems are already installed in more than 1,000 hospitals and reference labs in the US.

The company intends to produce several million SARS-CoV-2 antibody tests over the next month and to ramp up the production thereafter.

Related Companies

Free Report
img

Build resilience in the face of COVID-19 disruption

COVID-19 has already affected our lives forever. The way we work, shop, eat, seek medical advice, and socialize will all be different in the future. Quite how different remains to be seen, but all industries must plan for multiple eventualities. Are you interested in actionable insights on the business challenges induced by the pandemic? GlobalData's cross-sector report analyzes the significance of this major disruptive theme across industry verticals. It provides side-by-side research of alternative datasets to present you with unique quantitative analysis of the effects of COVID-19 and how these differ across sectors. Additionally, it offers qualitative analysis of each sector and analyzes COVID-19’s impact on leading companies. Whatever your company’s imminent strategic plans, the long-lasting impact of COVID-19 must not be overlooked. Find out how to futureproof your business operations – download our report today.
by GlobalData
Enter your details here to receive your free Report.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. The top stories of the day delivered to you every weekday. A weekly roundup of the latest news and analysis, sent every Friday. The medical device industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Medical Device Network